Molecular & Cellular Oncology (Sep 2017)
JumonjiC demethylase inhibitors show potential for targeting chemotherapy-resistant lung cancers
Abstract
Resistance to standard taxane-platin chemotherapy and tumor relapse are a major challenge in the treatment of non-small cell lung cancers (NSCLC). Our recent study identified JumonjiC demethylase inhibitors as a highly potent therapeutic strategy for targeting chemoresistant tumors and for preventing the emergence of drug-tolerant clones from taxane-platin treated NSCLCs.
Keywords